



06-07-01

03C9 #4

PATENT
514429-3647.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Fleckenstein et al.
U.S. Serial No. : 09/836,077
Filing Date : April 16, 2001
For : HUMAN SEMAPHORIN L (H-SEMAL) AND
CORRESPONDING SEMAPHORINS IN OTHER
SPECIES


745 Fifth Avenue, New York, NY 10151


EXPRESS MAIL

Mailing Label Number: EL 742694713 US

Date of Deposit: June 06, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents and Trademarks, Washington, DC 20231.


(Typed or printed name of person mailing paper or fee)


(Signature of person mailing paper or fee)

**AMENDMENT IN RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR
AMINO ACID SEQUENCE DISCLOSURES**

Assistant Commissioner for Patents
Box Sequence
Washington, D.C. 20231

Dear Sir:

This is in response to the Office Communication containing the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence mailed on June 1, 2001. The Office Communication set a one-month period for response. Applicants respectfully request acceptance of the enclosed Computer Readable form (CRF on diskette) and the printed copy of the sequence listing (identical to the sequence listing submitted for parent application U.S. serial number 09/112,904), the required Statements under

09836077-060601

37 C.F.R. §1.821 (f) and (g) (below), and please amend the above-captioned application as follows:

IN THE SPECIFICATION:

Please amend the specification as follows:

Immediately after page 90 and before the first page of claims (page 91), if appropriate, please insert the enclosed pages identified as --Sequence Listing--.

REMARKS

The examiner's attention is respectfully drawn to the fact that the sequence listing in this application is identical to that of predecessor parent application U.S. Serial No. 09/112,904 filed July 9, 1998. It is respectfully requested that the U.S. PTO use the electronic version of the sequence listing in that prior application, making any necessary changes therein for this application, e.g., as to Serial Number and filing date.

It is believed that the Sequence Listing conforms to the requirements of 37 C.F.R. §1.823(b). The Statements required by 37 C.F.R. §1.821(f) and (g) are set forth below.


Pursuant to 37 C.F.R. §1.821(f), the undersigned attorney hereby states that the content of the CRF and paper copy submitted herewith, and the computer readable copy of the Sequence listing submitted in U.S. Serial No. 09/112,904 in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same.

Pursuant to 37 C.F.R. §1.821(g), the undersigned attorney of record hereby states that this submission, filed in accordance with 37 C.F.R. §1.821(g), does not contain new matter. In view of the amendments, remarks and enclosures herewith, the application complies with the requirements for computer readable disclosure of the biological sequences under 37 C.F.R. §1.821-1.825.

However, if any fees are required, or if any overpayment has been made, please charge such fee, or credit any overpayment, to Deposit Account 50-0320.

Respectfully submitted,
FROMMER LAWRENCE & HAUG LLP

By:



Thomas J. Kowalski
Reg. No. 32,147

Enclosures: Printed copy and CRF (diskette) of Sequence Listing;
Copy of Notice to Comply; and
Return receipt postcard.

093607-0604
FO9090-209E860